Conventional coronary artery bypass grafting (CCAB) is one of the most frequently performed operations and, in specific subgroups, significantly improves survival, symptoms, and quality of life compared with nonsurgical management of coronary artery disease.1 However, these benefits are tempered by perioperative risks, including mortality (1-3%), stroke (2%), myocardial infarction (1-2%), exposure to allogeneic blood transfusion (30-90%), atrial fibrillation (30%), and cognitive dysfunction (50-75%).2–5 Portions of these morbidities have been attributed to the use of cardiopulmonary bypass (CPB), cardioplegic cardiac arrest, aortic cannulation, and cross clamping. Consequently, there has been increasing interest in techniques that avoid CPB, such as off-pump coronary artery bypass grafting (OPCAB).6,7
Numerous studies have been published comparing clinical outcomes after OPCAB versus CCAB. The majority of earlier trials were nonrandomized comparisons of low-risk patients undergoing single- or double-vessel bypass, with the potential risk of unbalanced baseline patient characteristics leading to bias in favor of either OPCAB or CCAB. More recently, nonrandomized comparisons of high-risk patients and randomized comparisons of mixed-risk patients have been published. However, some of these trials have focused on surrogate primary endpoints (such as inflammatory mediators), and have had insufficient statistical power to adequately explore clinically important outcomes, which occur infrequently, such as death, stroke, and myocardial infarction. There remains considerable uncertainty as to the role of OPCAB for patients across the full spectrum of risk groups.
The purpose of this evidence-based consensus statement is to systematically review and, where appropriate, meta-analyze the randomized and nonrandomized evidence specifically comparing OPCAB to CCAB and to provide consensus statements that clarify the role of OPCAB and CCAB for coronary revascularization in low- and high-risk surgical patients.
A two-day consensus conference was held in Paris, France, May 21-22, 2004, under the auspices of The International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS). The conference was conducted according to the ACC/AHA standards for the development of clinical practice guidelines [http://www.acc.org/clinical/manual/manual_index.htm accessed April 19, 2004]. A subcommittee of consensus experts performed a literature search for clinical trials in Medline and the Cochrane Library using the keywords ‘off-pump’ and ‘coronary bypass surgery’ and collated all published manuscripts on OPCAB versus CCAB, for review prior to the Consensus Conference. The Steering Committee of the 2004 ISMICS Consensus Panel developed six questions central to the controversies presently surrounding the field of OPCAB surgery. These served to focus the systematic review, discussion, and testimony given by the expert panel at the Consensus Conference. Published evidence, such as systematic reviews or meta-analyses of controlled clinical trials, was sought to inform each of these six questions. When systematic reviews or meta-analyses were not found, a subgroup of the consensus panel performed a systematic review and, when required, meta-analysis of all randomized8 and nonrandomized control trials9,10 through May 2004 that compared mortality, morbidity, and resource utilization of OPCAB versus CCAB. The patient groups examined included low-risk, high-risk, and mixed-risk populations.
Summary data from the systematic review and meta-analyses were presented at the Consensus Conference. The consensus panel provided evidence and/or expert opinion to formulate statements and recommendations regarding OPCAB surgery in various patient populations.
These were assessed by classes of support and levels of evidence according to the classifications of the ACC/AHA [http://www.acc.org/clinical/manual/manual_index.htm accessed April 19, 2004]. Classes of recommendation were defined as follows:
Conditions for which there is evidence and/or general agreement that a given procedure or therapy is useful and effective;
Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness or efficacy of performing the procedure or therapy;
Class II a.
Weight of evidence or opinion is in favor of usefulness or efficacy;
Class II b.
Usefulness or efficacy is less well established by evidence or opinion;
Conditions for which there is evidence and/or general agreement that a procedure or therapy is not useful or effective and in some cases may be harmful.
These recommendations were based on the following levels of evidence:
The data were derived from multiple randomized clinical trials;
The data were derived from a single randomized study or from nonrandomized studies;
The consensus opinion of experts was the primary source of recommendation.
Systematic Review & Meta-Analysis:
The methodology and results of the systematic review and meta-analysis of 37 randomized trials of mixed-risk populations undergoing OPCAB or CCAB has been previously described.8 Since this previous publication did not analyze combined results for graft patency, we conducted a pooled analysis of randomized trials reporting graft patency.
Two meta-analyses of nonrandomized trials of mixed-risk populations were identified during searches of the medical literature;9,10 therefore a separate meta-analysis for this population was not conducted.
No systematic reviews or meta-analyses of high-risk populations were identified. Therefore we conducted a full meta-analysis for this patient group. The methodology for the systematic review and meta-analysis of trials of high-risk groups undergoing OPCAB or CCAB is described below. Prior to the consensus conference, a comprehensive search was undertaken, in accordance with the Cochrane Collaboration,11 to identify all published randomized and nonrandomized trials of OPCAB versus CCAB, in all languages. MEDLINE, Cochrane CENTRAL, EMBASE, Current Contents, DARE, NEED, INAHTA databases were searched from the date of their inception through May 2004. The processes of comprehensive literature search and systematic review followed the methodologies and policies of the ACC/AHA Task Force on Practice Guidelines [http://www.acc.org/clinical/manual/manual_index.htm accessed April 19, 2004], while the meta-analysis was conducted in accordance with the ‘Quality of Reporting of Meta-Analyses’12 and Meta-Analysis of Observational Studies of Epidemiology13 recommendations.
All comparative trials of high-risk patients were included, whether randomized or nonrandomized, if they met each of the following criteria:1 comparison of OPCAB versus CCAB;2 adult patients undergoing single or multiple vessel bypasses; and3 reporting at least one pertinent clinical or economic outcome. Studies of robotic surgery and/or combined valve/coronary procedures were excluded.
All-cause mortality at 30 days and > 1 year were the primary endpoints. Secondary outcomes included postoperative incidence of stroke, cognitive dysfunction, acute myocardial infarction, recurrent angina, coronary reintervention, need for inotropes, need for intra-aortic balloon pump (IABP), atrial fibrillation, renal failure, mediastinitis/sternal wound infection, respiratory infection, need for blood transfusion, re-exploration for bleeding, duration of ventilation, ICU length of stay (LOS), hospital LOS, hospital costs, and quality of life (QOL). Postoperative atrial fibrillation, myocardial infarction, respiratory infection, mediastinitis/wound infection, and cognitive dysfunction were defined according to study authors’ definitions. Need for transfusion was defined as the proportion of patients requiring red blood cell transfusion during the intra- and postoperative periods, combined. Renal failure was defined per study authors’ definitions, typically a new rise in serum creatinine of > 50%, a decline in creatinine clearance of > 50%, or a requirement for dialysis. Duration of ventilation was measured in hours from end of surgery to time of tracheal extubation. Intensive care LOS and hospital LOS were measured in days, starting from end of surgery to ICU or hospital discharge, respectively.
Outcomes were analyzed as dichotomous variables, with the exception of duration of ventilation and LOS, which were analyzed as continuous variables when the mean and standard deviation were provided. For dichotomous variables, odds ratios and 95% confidence intervals [OR, 95% CI] were calculated. For continuous variables, the weighted mean difference [WMD, 95% CI] was calculated.
Heterogeneity was explored using the Q-statistic. Due to the low power of the Q-statistic,14 a higher threshold of P < 0.10 was used to suggest statistically significant heterogeneity across trials. In addition to the Q statistic, the I2 was calculated to quantify the degree of heterogeneity across trials that could not be attributable to chance alone.11,15,16
For each outcome, the fixed effect or random effects model was used when the Q-statistic suggested lack or presence of heterogeneity, respectively. Pooled effect estimates and heterogeneity between studies were analyzed by use of Comprehensive MetaAnalysis® (v1.0, Biostat, Englewood, NJ, USA 2002) and RevMan® (v4.2.2, Cochrane Collaboration, Oxford, England, 2003). Other than for the Q statistic, statistical significance was defined as P < 0.05. All tests of statistical significance were two-sided. Whenever possible, data analysis was by intention-to-treat.
Subanalyses for each high-risk group were planned a priori for the following patient risk groups: elderly (age > 70 years), obesity (BMI > 25 kg/m2), diabetes, renal failure, aortic disease, left main disease, left ventricular (LV) dysfunction, chronic obstructive or other pulmonary disease (COPD), urgent/emergent or re-do bypass, those requiring conversion from OPCAB to CCAB, and those with a high clinical risk score (i.e., usually EUROSCORE > 5 or Parsonnet score > 15), or mixed populations of patients with or more of the above risk factors. In subgroup analyses, the differences in relative size of effect were tested using a chi-square test for interaction or a chi-square test for trend.
For mixed-risk patient populations (unselected for high-risk characteristics), the results of a meta-analysis of 37 randomized clinical trials (3369 patients) comparing OPCAB versus CCAB (Level A) has been previously described.8 Since some randomized trials reported their results over a series of published reports, these 37 unique trials were reported across a total of 53 papers.17–69 One paper reported two randomized trials.17 Two meta-analyses of nonrandomized (Level B) OPCAB versus CCAB trials of mixed-risk populations have also been previously reported.9,10 The latter meta-analysis by Reston et al. combined nonrandomized trials with randomized trials; however the number of randomized trials was small relative to the nonrandomized trials. Therefore, the meta-analysis by Reston et al. will be referred to as Level B evidence.
For high-risk patient populations, we identified 45 eligible trials, including 26,349 patients, for our systematic review and meta-analysis (see Fig. 1). Of these, three were randomized controlled trials27,28,36 and 42 were nonrandomized trials.70–111 Most of the nonrandomized trials were retrospective cohort analyses, comparing patients undergoing OPCAB with patients undergoing CCAB over the same time period. A number of trials used data from patient registries, some of which may represent overlapping data across trials. All prospectively identified high-risk populations of interest were addressed in these trials. Subgroup analysis of individual risk groups was possible, except for the group of patients undergoing conversion from off- to on-pump or vice versa, since there was insufficient comparative information for this group. Publication bias was not identified for any of the clinical outcomes evaluated in high-risk groups.
Upon review of this evidence, the Consensus Panel addressed six prespecified questions, crafted statements and recommendations, and labeled each statement with the highest available level of evidence.
Question 1: Is OPCAB surgery associated with similar all-cause mortality at 30 days and > 1 year compared to CCAB surgery?
Early Mortality (up to 30 days):
In randomized trials of mixed-risk groups, no differences were found in any trial for mortality at 30 days (29 RCTs, Level A).17,26–28,30–32,34–37,40–44,47,49,51,52,56–59,62,63,67,68 Pooled analysis of these randomized trials found no difference in 30-day mortality (OR 1.02, 95%CI 0.58-1.80, P = 0.9; n = 3,082 patients in 29 RCT studies).8 (see Table 1) Considering that the pooled risk of mortality was 1.2% for OPCAB and 1.0% in the CCAB, and given that the absolute difference in mortality between the groups was so small (0.2%), it is clear that significant differences in mortality (if they exist at all) are unlikely to be found in patients of mixed- (generally low) risk groups similar to those included in these randomized trials. To find a mortality difference of 0.2%, very large trials (i.e., of > 85,000 patients) would be required.8
While pooled Level A evidence has had inadequate sample size to detect this small potential difference in mortality when low-risk groups are studied, there is a large body of retrospective studies (Level B) of mixed-risk patients showing reduced mortality at 30 days in OPCAB when compared with CCAB. Two meta-analyses of mixed-risk groups that included nonrandomized controlled trials (Level B)9,10 found reduced risk of mortality at 30 days with OPCAB versus CCAB. Reston et al. found a 36% reduction in risk of early mortality (OR, 0.64, 95%CI 0.54-0.75, P < 0.0000001; n = 39,647 patients in 43 Level A and B studies combined).10 Beattie et al. found a 21% reduction in mortality (OR 0.79, 95%CI 0.71-0.89; P < 0.0001; n = 159,845 patients in 7 studies).9 The apparent discrepancy between Level A and Level B evidence for early mortality may be related to inclusion of higher-risk groups in Level B studies. However, bias in patient selection or management (including surgeon-related differences between groups) cannot be excluded.
Late Mortality (up to 3 years):
In randomized trials of mixed-risk groups, no differences were found in any trial for mortality at 1 to 3 years (6 RCTs, n = 1,135) (Level A).17,31,49,52,59 Pooled analysis of these randomized trials found no difference in mortality at 1 to 3 years (OR 0.88, 95%CI 0.41-1.88, P = 0.8; n = 1,135 patients in 6 RCT studies) (Level A).8 (See Table 1)
Mortality in Converted OPCAB Patients to CPB:
A total of 20 out of 37 identified randomized controlled trials [Level A]17,27,30,31,38,40,42-45,48,50,52,56-58,63,64,68 reported conversions of patients from off-pump to on-pump surgery. Rates of conversion in these trials ranged from 0% to over 20%, with an overall average rate of 8% of OPCAB patients converted to on-pump surgery.8 However, no randomized trials reported outcomes separately for patients who were urgently converted.
A small body of Level B and C evidence (5 studies, reporting conversion rates of 5 to 13%, for a total of 175 converted patients) reports increased risk of mortality (i.e., absolute risk increase of 6 to 15%) for patients emergently converted from OPCAB to CCAB (Level B and C).112–116 Other adverse outcomes, including myocardial infarction, stroke, and multisystem organ failure were increased in urgently converted OPCAB patients.
When compared to CCAB in mixed-risk surgical groups, OPCAB results in similar [Level A] or reduced [Level B] risk of mortality at 30 days. At 1 to 3 years follow-up, mortality is similar between groups [Level A and Level B].
OPCAB should be considered a safe alternative to CCAB with respect to risk of mortality in patients undergoing surgical myocardial revascularization [Class I, Level A].
Question 2: Does OPCAB provide similar completeness of revascularization and graft patency when compared to CCAB?
Complete revascularization of all coronary arteries with stenoses > 70% has been a hallmark of surgical therapy for coronary artery disease and is important for long-term patient benefits.117–119 Level B evidence, especially nonrandomized retrospective reviews conducted early in the experience of OPCAB, generally showed fewer grafts performed per patient in the OPCAB groups relative to CCAB.120–122
Our meta-analysis of randomized trials reporting number of grafts (22/37 RCTs; n = 2,062 patients) showed a lower number of grafts per patient in the OPCAB group compared with CCAB [2.6 versus 2.8; P < 0.0001] (see Fig. 2a). While this difference is statistically significant, the clinical significance of 0.2 fewer grafts per patient is difficult to assess. When the data were analyzed separately for earlier trials (i.e., prior to and including the year 2000) and later trials (after the year 2000), the number of grafts per OPCAB patient increased, but the difference in grafts revascularized remained significantly different: 2.1 OPCAB versus 2.4 CCAB for earlier trials (P = 0.004), and 2.7 OPCAB versus 2.9 CCAB for later trials (P = 0.0006) (see Fig. 2a).
Completeness of revascularization was reported in only randomized trials.27,28,31,40,43,50,53 Carrier et al.27 and Czerny et al.31 reported significantly reduced completeness of revascularization in OPCAB group, whereas Covino,28 Khan,40 Legare,43 Nathoe50 and Puskas53 reported no difference in completeness of revascularization. Nonrandomized trials suggest that completeness of revascularization may be similar123,124 or decreased97,125 with OPCAB [Level B].
Four randomized trials [Level A] of OPCAB versus CCAB evaluated graft patency by angiography at time points ranging from in-hospital to 1 year postoperatively.40,44,50,53 Of 617 patients randomized in these studies, 451 underwent postoperative catheterization of 1343 grafts. Puskas et al.53 found no difference in graft patency prior to hospital discharge (622 grafts). Khan et al.40 found a decrement in graft patency in the OPCAB group at 3 months; in contrast, Lingaas et al.44found no significant difference at 3 months. At 1 year, Nathoe et al.50and Puskas et al.53 found no significant difference in graft patency between the OPCAB and CCAB groups. Meta-analysis of graft patency at 1 year confirmed no significant difference between OPCAB and CCAB groups (Fig. 2b). The discrepant results of Khan et al. may result from divergent usage of radial artery conduits and limited surgeon experience in OPCAB techniques, as acknowledged by the authors.40
Nonrandomized studies [Level B] report similar patency of arterial conduits for on- and OPCAB.126–129 Level B and Level C studies130–132 have demonstrated excellent arterial graft patency after OPCAB (94% to 100% at 6 months to 6 years follow-up) with no significant differences compared with CCAB in Level B studies.126–129 While some nonrandomized studies report a decrement in vein graft patency of up to 24%,128,132 others129 report similar vein graft patency after OPCAB versus CCAB. [Level B]
The ultimate clinical expression of reduced patency is increased need for repeat revascularization over time. Meta-analysis of randomized trials [Level A] has not shown a significantly increased risk of need for repeat revascularization at 1 to 3 years postbypass surgery (OR 1.61, 95%CI 0.71-3.65, P = 0.3; n = 1,120 in 6 studies).17,31,49,52,59 Longer follow-up is not yet available.
The number of grafts performed and completeness of revascularization is slightly reduced with OPCAB compared with CCAB [Level A and Level B]. These differences have not translated into measurable increases in need for repeat revascularization or reintervention at 1 to 3 years follow-up [Level A]. Graft patency is similar after OPCAB and CCAB [Level A and Level B]. Completeness of revascularization and patency likely depend on surgeon expertise [Level C].
With appropriate use of modern stabilizers, heart positioning devices and adequate surgeon experience, similar completeness of revascularization and graft patency can be achieved with OPCAB [Class IIa, Level A]. Longitudinal follow-up of randomized trials to explore the long-term impact of OPCAB on recurrent ischemia and need for reintervention should be performed.
Question 3: What are the rates of postoperative stroke, acute myocardial infarction, atrial fibrillation, recurrent angina, reintervention for ischemia, renal failure, blood transfusion, re-exploration for bleeding, inotrope dependence, intra-aortic balloon pump (IABP) placement, mediastinitis/wound infection, and respiratory infections after OPCAB versus CCAB surgery?
Some but not all randomized trials showed significant reduction in atrial fibrillation,17,49 red blood cell transfusions,17,26,35,40,49,52,62,68 inotrope requirements,17,26,34 and respiratory infections17 with OPCAB compared to CCAB. In pooled analysis of randomized clinical trials evaluating outcomes in patient populations with mixed-risk factors, OPCAB reduces the incidence of atrial fibrillation (OR 0.58, 95%CI 0.44-0.77, P < 0.0001; n = 2,425 patients in 17 RCTs), red blood cell transfusions (OR 0.43, 95%CI 0.29-0.65, P < 0.0001; n = 2,412 patients in 17 RCTs), inotrope requirements (OR 0.48, 95%CI 0.32-0.73, P < 0.0001; n = 1,655 patients in 16 RCTs), and respiratory infections (OR 0.41, 95%CI 0.23-0.74, P < 0.0001; n = 896 patients in 7 RCTs) when compared with CCAB (Table 1).8 [Level A]
In patient populations of mixed-risk factors, no randomized trials showed a significant reduction in stroke, myocardial infarction, acute renal failure, IABP requirement, mediastinitis/wound infection, angina recurrence, and need for reintervention within 30 days when compared with CCAB. Similarly, in pooled analysis of these randomized trials, OPCAB had a similar incidence of stroke, myocardial infarction, acute renal failure, IABP requirement, mediastinitis/wound infection, angina recurrence, and need for reintervention within 30 days when compared with CCAB.8 [Level A]
Furthermore in patient populations of mixed-risk factors, OPCAB, when compared with CCAB at mid-term (1 to 3 years), did not alter the incidence of stroke, myocardial infarction, angina recurrence, and need for reintervention.8 [Level A]
In mixed-risk patient populations, OPCAB was associated with a reduction in markers of subsystem organ dysfunction: troponin T, troponin I, and inflammatory response, compared to CCAB.19,20,25,26,30,32,35,37,46,47,51,52,55,62,63,66,67 [Level A]
Evidence from a large body of retrospective studies [Level B] and two meta-analyses including Level B evidence of mixed-risk surgical groups9,10 show reduced stroke risk with OPCAB versus CCAB. Reston et al. showed a 45% reduction in the risk of stroke (OR 0.55, 95%CI 0.43-0.69, P < 0.0001; n = 34,126 patients in 38 studies],10 and Beattie et al. showed a 40% reduction in the risk of stroke (OR 0.60, 95%CI 0.52-0.69, P < 0.0001; n = 192,682 in 11 studies).9 Reston et al. included 53 studies in their meta-analysis (10 RCTs, of which 3 were duplicates; plus 43 observational studies). They also reported a significant reduction for myocardial infarction (OR 0.58, 95%CI 0.44 –0.76, P = 0.00009; n = 24,322 patients in 26 studies), atrial fibrillation (OR 0.69, 95%CI0.58-0.81, P = 0.00001; n = 22,092 patients in 28 studies), renal failure (OR 0.62, 95%CI 0.50-0.78, P = 0.00003; n = 20,845 patients in 17 studies), reoperation for bleeding (OR 0.54, 95%CI 0.44-0.67, P < 0.0001; n = 33,442 patients in 24 studies), wound infection (OR 0.l55, 95%CI 0.37-0.83, P = 0.004; n = 16,039 patients in 17 studies), and reintervention (OR 3.63, P = 0.0001; n = 2,823 patients in 7 studies).10 [Level B]
Meta-analysis of Level A evidence showed no significant difference in the incidence of stroke at 30 days (OR 0.68, 95%CI 0.33-1.40, P = 0.3; n = 2,859 in 21 RCTs).8 Whether the discrepancy between Level A and Level B evidence is related to insufficient statistical power in Level A trials or to a greater apparent benefit of OPCAB in higher-risk groups included in Level B trials remains uncertain.
In mixed-risk patient populations, OPCAB is associated with reduced risk of perioperative atrial fibrillation, red blood cell transfusion, inotrope requirements, and respiratory infections [Level A]. OPCAB is also associated with reduction in serum levels of myocardial enzymes and inflammatory mediators [Level A].
Level B evidence suggests potential reduction in additional perioperative morbidity (stroke, myocardial infarction, renal failure, reoperation for bleeding, wound infection, and reintervention).
At up to 3 years’ follow-up, the risk of stroke, myocardial infarction, angina recurrence, and need for reintervention similar between OPCAB and CCAB [Level A].
OPCAB is recommended in patients undergoing surgical myocardial revascularization to reduce perioperative morbidity [Class I, Level A].
Question 4: Are there differences in cognitive function and quality of life outcomes between OPCAB and CCAB?
Early: Significant reduction in selected measures of cognitive decline was found up to 2 weeks postoperatively in two randomized studies.42,68 One randomized study did not show any difference in cognitive outcomes between OPCAB and CCAB at month.60 Pooled analysis of these randomized trials showed a reduction in patients experiencing cognitive decline (OR 0.57, 95%CI 0.21 to 1.54, P = 0.04; n = 335 in 3 studies),8 but the results were not statistically significant when heterogeneity between results was accounted for statistically (P = 0.04 with fixed effects model; P = 0.3 with random effects model).
Of four randomized trials32,60,68,69 reporting cognitive outcomes at 2 to 6 months, 3 showed significant difference32,68,69 and showed no significant difference60 in selected measures of cognitive decline. Pooled analysis of 3 of these randomized trials60,68,69 (the fourth trial32 did not meet criteria for meta-analysis) showed a 46% reduction in the number of patients with cognitive dysfunction in the off-pump group at 2 to 6 months (OR 0.56, 95%CI 0.35-0.89, P = 0.01; n = 393 in 3 studies). (Table 1)8[Level A]
Four randomized trials compared cognitive function at year and did not find a difference in number of patients with cognitive decline in OPCAB versus CCAB groups.42,46,60,69 [Level A] Pooled analysis of these randomized trials showed no significant difference in number of patients with cognitive decline at 1 year (OR 0.91, 95%CI 0.57-1.46, P = 0.7; n = 334 in 2 trials).8 [Level A] No Level A or Level B studies of cognitive outcomes beyond 1 year were found. Comparative cognitive outcome after OPCAB and CCAB depends to a great extent upon the tests used, the time period of assessment, the definition of significant cognitive dysfunction, and the statistical methodology.133,134
There is additional rationale for improved results in OPCAB from studies of surrogate markers of brain dysfunction, such as measurement of differences in brain water [Level B],135,136 brain perfusion [Level A],48,63 and cerebral microemboli [Level A]69 [Level B].137 However, the clinical impact of these results is unclear.
Quality of Life:
Early: Two randomized controlled trials reported no significant differences between OPCAB and CCAB in QOL scores as measured by the EuroQOL and SF-36 at 4 to 6 weeks.53,60 [Level A] Pooled analysis of QOL results was not attempted, due to heterogeneity in definitions and endpoints.
Three randomized studies24,50,53 reported similar improvements in measures of quality of life after 1 year of follow-up, with no significant differences between OPCAB and CCAB groups [Level A]. Of nonrandomized trials reporting QOL, showed no difference73,125 and showed significantly improved QOL138 with OPCAB versus CCAB. [Level B]
OPCAB surgery may have a positive impact in mid-term (2 to 6 months) cognitive function [Level A]. For early (up to 30 days) and late cognitive function (1 year), no difference has been shown between OPCAB and CCAB [Level A]. Limited data suggest no difference in QOL outcomes at 1 month to 4 years [Level A].
* OPCAB may be recommended to minimize midterm cognitive dysfunction in patients undergoing surgical coronary revascularization. (Class IIa, Level A)
* OPCAB should be considered as an equivalent alternative to CCAB in regard to QOL for patients undergoing surgical myocardial revascularization. (Class I, Level A)
Question 5: Are there differences between OPCAB and CCAB surgery in resource utilization, including duration of ventilation, ICU length of stay (LOS), hospital LOS, and hospital costs?
A significant reduction in duration of ventilation,17,30,31,35,36,39,47,49,51 ICU stay,17,26,28,30,36 hospital stay,17,26,35,47,49 and in-hospital costs22,42,50,52,56 in OPCAB compared to CCAB has been confirmed by a large body of randomized trials [Level A]. Pooled analysis of randomized trials showed significant reductions in hospital stay (WMD –1.0 day, 95%CI –1.5 to –0.5 days, P < 0.0001; n = 1,384 patients in 17 RCTs), ICU stay (WMD –0.3 days, −0.6 to –0.1 day, P = 0.003; n = 1,266 patients in 15 RCTs), and duration of ventilation (WMD -3.4 hours, 95%CI –5.1 to –1.7 hours, P < 0.0001; n = 1,425 patients in 20 RCTs) (Table 1).8 [Level A] The reduction in direct hospital cost (Table 2) is secondary to a reduction in ICU stay, hospital stay, blood transfusion, and a lower incidence of postoperative complications.
Substantial evidence exists for a reduction in resource utilization, including duration of ventilation, ICU and hospital LOS, in OPCAB versus CCAB surgery [Level A]
OPCAB is recommended in patients undergoing surgical myocardial revascularization to reduce the duration of ventilation, ICU and hospital stays, and resource utilization. [Class I, Level A]
Question 6: Are there differences in a) mortality, b) morbidity and c) QOL and resource utilization in high-risk patients having OPCAB versus CCAB surgery?
a) Mortality in High-Risk Patients
Only randomized trials of high-risk patients were identified: in patients with COPD28,36 and in patients with at least high-risk factor.27 None of these trials found a significant difference in mortality; however their combined sample size was low (n = 160) [Level A].
Forty-two nonrandomized trials of high-risk patients were identified, a number of which demonstrated significant reduction in mortality after OPCAB versus CCAB in various high-risk patient subsets [Level B]. Our pooled analysis of Level B evidence (Table 3a) showed a significantly improved survival when all high-risk patient groups were combined (OR 0.58, 95%CI 0.49-0.68; P < 0.0001, n = 24,989) [Level B]. In addition, pooled analysis showed that mortality was reduced in patient subgroups with the following high-risk factors (Table 3a, and Fig. 3a) [Level B]:
* Euroscore > 598,99,102,109,139
* LV dysfunction70,73,75,76,78,82,92–94
* Atheromatous Aorta75,140,141
* Presence of at least high-risk factor27,71,73,75,84–86,97,105,107
In contrast, no effect on early mortality was found for OPCAB versus CCAB in the following high-risk patient subgroups [Level B] (Fig. 3a):
* Increased age73,75,77,80,90,96,100,101
* Left Main Disease74,79
* Renal Dysfunction72,75,83,108
OPCAB is associated with reduced mortality in pooled analysis of high-risk patients and in specific high-risk subgroups of patients identified above [Level B].
b) Morbidity in High-Risk Patients
Figures 3b-i and Tables 3b-k outline the meta-analysis results for morbidity in high-risk patients and their subgroups. Overall, our pooled analysis of all high-risk groups combined showed that OPCAB significantly reduced risk overall for stroke, myocardial infarction, atrial fibrillation, transfusions, renal dysfunction, inotrope requirement, IABP, and reoperation for bleeding compared with CCAB. No significant difference between OPCAB and CCAB was found for mediastinitis/wound infection or pulmonary complications (including respiratory infections) when all high-risk groups were combined.
In our pooled analysis of individual patient risk groups, OPCAB was associated with lower morbidity when compared to CCAB in patients with the following identifiable risk factors (Tables 3b-k) [Level B]:
* Euroscore > 5: AMI98,99,102,109,139
* Age > 75: Stroke,75,80,90,100,101 AF,90,96,101,139 Transfusions,73,75,90,96 IABP77,96
* Diabetes: Stroke,88,95,103 AF88
* Renal Failure: Stroke,72,75,108 Transfusions,75,83 Dialysis,72,75 Inotropes72
* LV dysfunction: Transfusions,70,73,75,76,78 Renal Dysfunction,70,93,139 Inotropes76
* Left Main Disease: AF,79 Transfusions,78,79,104 Inotropes78,79,104
* Redo or Urgent/Emergent CABG: Renal dysfunction75,106
* COPD: Transfusions75
* Presence of at least high-risk factor: Stroke,27,71,73,75,84–86,105,107 AF,71,84–86,97,107 Transfusions,27,71,73,75,84–86,105,107 Inotropes,71,86,105 Reoperation for bleeding73,84-86,105; IABP71,85,86,105,107
In general, perioperative risks were decreased in OPCAB versus CCAB, with the possible exception of increased inotrope requirement in the elderly96 and in those with EUROSCORE > 5.139
OPCAB is associated with reduced morbidity in pooled analysis of high-risk patients and in specific high-risk subgroups of patients identified above [Level B].
c) Quality of Life and Resource Utilization in High-Risk Patients:
Nonrandomized trials of OPCAB versus CCAB measuring cognitive decline in high-risk patients were not found. Three nonrandomized studies of high-risk patients with LV dysfunction,93 increased age and urgent/emergent surgery,91 and various high-risk factors73 did not demonstrate significant differences in measures of quality of life after short- to mediumterm followup for OPCAB and CCAB groups [Level B]. Aggregate analysis of QOL results was not possible in this meta-analysis due to heterogeneity.
Hospital Length of Stay.
Figure 4a and Table 4a outline the LOS results for high-risk patients and their subgroups. Pooled analysis of all high-risk surgical groups showed significant reduction in hospital stay. In the pooled analysis, significant reduction in hospital stay was also found for the following high-risk groups:
* Euroscore > 598,99,102,110
* LV dysfunction73,82,86,92
* Aortic disease81
* Redo or Urgent/Emergent CABG91,142
* Presence of at least one high-risk factor73,85,97
ICU Length of Stay.
Figure 4b and Table 4b outline the ICU LOS results for high-risk patient groups. Pooled analysis of all high-risk surgical groups showed no significant difference in ICU stay. However, in the pooled subgroup analysis, significant reduction in ICU length of stay was found for the following high-risk groups:
* Age > 7573,101
* LV dysfunction70,73,78,82,92
* Left Main
Figure 4c and Table 4c outline the results of ventilation time for high-risk patient groups. Pooled analysis of all high-risk surgical groups showed significant reduction in ventilation time. In the pooled analysis, significant reduction in duration of ventilation was found for the following high-risk groups:
* Age > 7573,100,101
* LV dysfunction70,73,78,82,92
* Left Main Disease79
Three nonrandomized trials were identified that evaluated costs in patients with end-stage renal disease83 or increased age90,101 Each study reported a reduction in costs of approximately 15-25% for OPCAB compared to CCAB.
OPCAB is associated with similar QOL outcomes and reduced resource utilization in specific high-risk patients identified above [Level B].
* OPCAB should be considered in high-risk patients undergoing surgical revascularization and in patients with the above-identified risk factors to reduce perioperative mortality when compared to CCAB (Class IIa, Level B).
* OPCAB should be considered in patients undergoing surgical revascularization with the above-identified risk factors to reduce perioperative morbidity and resource utilization when compared to CCAB. (Class IIa, Level B).
* Future randomized trials should evaluate the impact of OPCAB on survival and morbidity in high-risk patients.
Morbidity and Mortality
OPCAB seeks to avoid the morbidity attributable to cardiopulmonary bypass during conventional CCAB. As such, OPCAB attempts to improve upon an operation which has been refined over 40 years and which yields excellent clinical results. With respect to endpoints that occur infrequently, including death, MI and stroke, randomized trials of enormous sample size would be required to conclusively demonstrate differences in outcomes between treatment groups among low-risk patients. For example, given the aggregate incidence of death, stroke, and myocardial infarction from meta-analysis of Level A studies, approximately 85,000, 6000, and 12,000 patients, respectively, would be required to demonstrate statistically significant differences for these endpoints. Outcomes occur more frequently are more easily compared between groups, and randomized trials of OPCAB have reported superior results in terms of numerous morbidity endpoints, including atrial fibrillation, inotrope use, transfusion requirement, respiratory infections, ventilation time, and length of stay.8 However, randomized trials [Level A] to date have enrolled relatively few patients and these have generally been selected, lower-risk or mixed-risk patient populations, potentially reducing the generalizability of results.
Retrospective, nonrandomized comparisons [Level B] provide greater statistical power but are subject to criticism regarding potential bias in patient selection, management and reporting.9,10 Rigorous meta-analysis of results from numerous peer-reviewed publications allows analysis of patient subgroups and application of sophisticated statistical methods to account for heterogeneity of patient populations and outcomes. Nonetheless, while the meta-analyses described above extend the generalizability of conclusions reached in the literature regarding OPCAB, the relative benefits of OPCAB versus CCAB for some endpoints in some patient populations remain to be conclusively proven. The majority of current Level B evidence suggests that patients with comorbidities known to be associated with increased perioperative risk after CCAB may benefit most from OPCAB. (Fig. 5) Future prospective randomized studies designed to determine whether OPCAB is associated with reduced operative mortality or infrequently occurring major morbidities (stroke, MI) compared to CCAB should be conducted in high-risk patients.
Completeness of Revascularization and Graft Patency
It is important to note that techniques for both conventional CABG and OPCAB continue to evolve and improve over time. Moreover, OPCAB is known to have a relatively long surgeon learning curve, during which multivessel grafting—especially on the left lateral wall of the heart—may be challenging. Thus, numerous comparisons of OPCAB and CCAB have reported fewer grafts per patient in the OPCAB groups. This may reflect surgeon selection of patients requiring only anterior and right-sided grafts early in their learning curves, rather than incomplete revascularization. As OPCAB techniques and enabling instrumentation have improved, the number of grafts performed per patient has increased in more recent studies.53 Many surgeons now routinely approach patients requiring lateral wall grafting off-pump, achieving complete revascularization of patients with multivessel coronary disease. The decision between OPCAB and CCAB for any individual patient should weigh several factors, including the likely risks and benefits of the two approaches for that particular patient, the experience level of the surgeon, and the degree of complexity of the coronary revascularization required. Completeness of revascularization should not be sacrificed in order to avoid cardiopulmonary bypass, except in very rare circumstances.
Excellent graft patency has been demonstrated after OPCAB in both prospective randomized and retrospective studies. However, optimal graft patency has been dependent on the adoption of sophisticated stabilization and positioning devices.132 Intraoperative assessment of graft patency by transit time Doppler or other methods may be of benefit, especially during each surgeon’s OPCAB learning curve. Patency is likely dependent on surgeon experience in OPCAB surgery [Level C].
There is general agreement that coagulopathy after OPCAB is infrequent and that a relative hypercoagulability may exist after OPCAB compared to CCAB.143 Strategies for platelet inhibition in the perioperative period vary widely between centers. Future investigations of graft patency after OPCAB versus CCAB should account for confounding effects of surgeon experience, different stabilization devices/techniques, and use of various conduits. Further research should also focus on need for reintervention for ischemia over the long term after OPCAB versus CCAB.
Comparisons of cognitive outcome after OPCAB and CCAB depend, to an important degree, upon the tests used, the time of assessment, the definition of significant cognitive dysfunction, and the statistical methodology employed in analysis of outcomes. Three of randomized trials report less cognitive decline early after OPCAB. However, precise and reliable measurement of cognitive dysfunction remains limited by imperfect measurement tools and logistical difficulties of perioperative testing in coronary populations. Several studies [Level A and B] of surrogate endpoints (measurement of brain water, brain perfusion and cerebral emboli) showed lesser degrees of injury after OPCAB.48,63,69,135–137 However, these surrogates have not been conclusively correlated with clinically important outcomes to date. Longer-term cognitive function and subgroup analyses remain to be evaluated.
Costs and Hospital Resources
Five Level A studies reported significant cost reductions in favor of OPCAB surgery (Table 2). However, due to systematic differences between different healthcare systems and hospitals, costs are highly variable. It is likely that optimal reduction in resource utilization with OPCAB will require significant reorganization and re-engineering of each hospital’s cardiovascular division and clinical pathway to take advantage of reduced morbidity after OPCAB.
The decision between OPCAB and CCAB should be governed by careful consideration of the clinical importance of these potential benefits in light of operator experience and patient suitability for OPCAB.
OPCAB seeks to improve patient outcomes by avoiding morbidity attributable to cardiopulmonary bypass. A growing body of literature documents that numerous morbidities are reduced after OPCAB versus CCAB. However, the sample size of randomized controlled trials to date has limited statistical power to demonstrate differences in outcomes that occur infrequently. Retrospective comparisons are subject to criticism for potential bias in patient selection and management. Only a large prospective, randomized trial evaluating numerous endpoints will firmly answer outstanding questions regarding the relative merits of on- and off-pump surgical coronary revascularization, particularly in high-risk patients. However, rigorous meta-analysis of pooled Level A and Level B evidence allows several recommendations to be made in this Consensus Conference:
1. OPCAB should be considered a safe alternative to CCAB with respect to risk of mortality in patients undergoing surgical myocardial revascularization [Class I, Level A].
2. With appropriate use of modern stabilizers, heart positioning devices and adequate surgeon experience, similar completeness of revascularization and graft patency can be achieved with OPCAB [Class IIa, Level A]
3. OPCAB is recommended in patients undergoing surgical myocardial revascularization to reduce perioperative morbidity [Class I, Level A]
4. OPCAB may be recommended to minimize midterm cognitive dysfunction in patients undergoing surgical coronary revascularization. [Class IIa, Level A]
5. OPCAB should be considered as an equivalent alternative to CCAB in regard to QOL for patients undergoing surgical myocardial revascularization. [Class I, Level A]
6. OPCAB is recommended in patients undergoing surgical myocardial revascularization to reduce the duration of ventilation, ICU and hospital stays, and resource utilization. [Class I, Level A]
7. OPCAB should be considered in high-risk patients undergoing surgical revascularization and in patients with the above-identified risk factors to reduce perioperative mortality, morbidity and resource utilization, when compared to CCAB [Class IIa, Level B] Source of Funding: This study is supported by an unrestricted education grant from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS), a nonprofit medical organization which derives some funding from corporations that have interest in the field of cardiothoracic surgery.
All participants on the Expert Consensus Panel read and signed conflict of interest statements, making full disclosure at the time of the consensus conference. This Expert Consensus Statement is endorsed by ISMICS, an international organization of cardiothoracic surgeons with special interest in minimally invasive surgery.
1. Hueb W, Soares PR, Gersh BJ, et al., Oliveira SARJA. The medicine, angioplasty, or surgery study (MASS-II): a randomized controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol
2. SOS. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomized controlled trial. Lancet 2002;360:965-970.
3. Stover EP, Siegel LC, Parks R., Levin J, Body SC, Maddi R, D’Ambra MN. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24-institution study. Institutions of the Multicenter Study of Perioperative Ischemia Research Group. Anesthesiology
4. Stamou SC, Hill PC, Dangas G, et al., Corso PJ. Stroke after coronary artery bypass: incidence, predictors, and clinical outcome. Stroke
5. Mathew JP, Parks R, Savino JS, et al. for The Multicenter Study of Perioperative Ischemia Research Group. Atrial fibrillation following coronary artery bypass graft surgery. Predictors, outcomes, and resource utilization. JAMA
6. Ascione R, Caputo M, Angelini GD. Off-pump coronary-artery bypass grafting: not a flash in the pan. Ann Thorac Surg
7. Rose EA. Off-pump coronary-artery bypass surgery. N Engl J Med
8. Cheng DC, Bainbridge D, Martin JA, Novick RJ. Does off-pump coronary artery bypass reduce mortality, morbidity and resource utilization when compared to conventional coronary artery bypass? A meta-analysis of randomized trials. Anesthesiology
9. Beattie S, Wijeysundera D, Djaiani G, et al. Off-pump coronary artery surgery for the reduction of perioperative mortality and morbidity: A meta-analysis. Anesth Analg
10. Reston JT, Tregear SJ, Turkelson CM. Meta-analysis of short-term and mid-term outcomes following off-pump coronary artery bypass grafting. Ann Thorac Surg
11. Cochrane Reviewers’ Handbook 4.2.1 (updated December 2003). Chichester, UK: John Wiley & Sons, Ltd.; 2004.
12. Moher D, Cook DJ, Eastwood S, et al. for the QUOROM Group. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet
13. Stroup DF, Berlin JA, Morton SC, et al. (MOOSE) Group. Meta-analysis of observational studies in epidemiology. A proposal for reporting. JAMA
14. Paul SR, Donner A. Small sample performance of tests of homogeneity of odds ratios in K 2 x 2 tables. Stat Med
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ
16. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med
17. Angelini GD, Taylor FC, Reeves BC, Ascione R. Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomised controlled trials. Lancet
18. Ascione R, Caputo M, Calori G, et al. Predictors of atrial fibrillation after conventional and beating heart coronary surgery. A prospective, randomized study. Circulation
19. Ascione R, Lloyd CT, Underwood MJ, et al. Inflammatory response after coronary revascularization with or without cardiopulmonary bypass. Ann Thorac Surg
20. Ascione R, Lloyd CT, Gomes WJ, et al. Beating versus arrested heart revascularization: evaluation of myocardial function in a prospective randomized study. Eur J Cardiothorac Surg
21. Ascione R, Lloyd CT, Underwood MJ, et al. On-pump versus off-pump coronary revascularization: Evaluation of renal function. Ann Thorac Surg
22. Ascione R, Lloyd CT, Underwood MJ, et al. Economic outcome of off-pump coronary artery bypass surgery: A prospective randomized study. Ann Thorac Surg
23. Ascione R, Williams SV, Lloyd CT, et al. Reduced postoperative blood loss and transfusion requirement after beating-heart coronary operations: A prospective randomized study. J Thorac Cardiovasc Surg
24. Ascione R, Reeves BC, Taylor FC, et al. Beating heart against cardioplegic arrest studies (BHACAS 1 and 2): quality of life at mid-term follow-up in two randomised controlled trials. Eur Heart J
25. Baker RA, Andrew MJ, Ross IK, Knight JL. The Octopus II stabilizing system: biochemical and neuropsychological outcomes in coronary artery bypass surgery. Heart Surg Forum
26. Caputo M, Yeatman M, Narayan P, et al. Effect of off-pump coronary surgery with right ventricular assist device on organ function and inflammatory response: A randomized controlled trial. Ann Thorac Surg
27. Carrier M, Perrault LP, Jeanmart H, et al. Randomized trial comparing off-pump to on-pump coronary artery bypass grafting in high-risk patients. Heart Surg Forum
28. Covino E, Santise G, Di Lello F, De Amicis V., Bonifazi R, Bellino I, Spampinato N. Surgical myocardial revascularization (CABG) in patients with pulmonary disease: beating heart versus cardiopulmonary bypass. J Cardiovasc Surg (Torino)
29. Cox CM, Ascione R, Cohen AM, et al. Effects of cardiopulmonary bypass on pulmonary gas exchange: A prospective randomized study. Ann Thorac Surg
30. Czerny M, Baumer H, Kilo J, et al. Inflammatory response and myocardial injury following coronary artery bypass grafting with or without cardiopulmonary bypass. Eur J Cardiothorac Surg
31. Czerny M, Baumer H, Kilo J, et al. Complete revascularization in coronary artery bypass grafting with and without cardiopulmonary bypass. Ann Thorac Surg
32. Diegeler A, Hirsch A, Schneider F, et al. Neuromonitoring and neurocognitive outcome in off-pump versus conventional coronary bypass operation. Ann Thorac Surg
33. Dorman BH, Kratz JM, Multani MM, et al. A prospective randomized study of endothelin and postoperative recovery in off-pump versus conventional coronary artery bypass surgery. J Cardiothor Vasc Anesth
34. Gerola LR, Buffolo E, Jasbik W, et al. Off-pump versus on-pump myocardial revascularization in low-risk patients with one or two vessel disease: Perioperative results in a multicenter randomized controlled trial. Ann Thorac Surg
35. Gu YJ, Mariani MA, van Oeveren W, et al. Reduction of the inflammatory response in patients undergoing minimally invasive coronary artery bypass grafting. Ann Thorac Surg
36. Guler M, Kirali K, Toker ME, et al. Different CABG methods in patients with chronic obstructive pulmonary disease. Ann Thorac Surg
37. Gulielmos V, Menschikowski M, Dill H-M, et al. Interleukin-1, interleukin-6 and myocardial enzyme response after coronary artery bypass grafting - a prospective randomized comparison of the conventional and three minimally invasive surgical techniques. Eur J Cardiothorac Surg
38. Gulielmos V, Eller M, Thiele S, et al. Influence of median sternotomy on the psychosomatic outcome in coronary artery single-vessel bypass grafting. Eur J Cardiothorac Surg
39. Johansson-Synnergren M, Nilsson F, Bengtsson A, et al. Off-pump CABG reduces complement activation but does not significantly affect peripheral endothelial function: a prospective randomized study. Scand Cardiovasc J
40. Khan NE, De Souza A, Mister R, et al. A randomized comparison of off-pump and on-pump multivessel coronary-artery bypass surgery. N Engl J Med
41. Krejca M, Skiba J, Szmagala P, et al. Cardiac troponin T release during coronary surgery using intermittent cross-clamp with fibrillation, on-pump and off-pump beating heart. Eur J Cardiothorac Surg
42. Lee JD, Lee SJ, Tsushima WT, et al. Benefits of off-pump bypass on neurologic and clinical morbidity: A prospective randomized trial. Ann Thorac Surg
43. Legare J-F, Buth KJ, King S, Wood J, et al. Coronary bypass surgery performed off pump does not result in lower in-hospital morbidity than coronary artery bypass grafting performed on pump. Circulation
44. Lingaas PS, Hol PK, Lundblad R, et al. Clinical and angiographic outcome of coronary surgery with and without cardiopulmonary bypass: A prospective randomized trial. Heart Surg Forum
45. Lonn U, Peterzen B, Carnstam B, Casimir-Ahn H. Beating heart coronary surgery supported by an axial blood flow pump. Ann Thorac Surg
46. Lloyd CT, Ascione R, Underwood MJ, et al. Serum S-100 protein release and neuropsychologic outcome during coronary revascularization on the beating heart: A prospective randomized study. J Thorac Cardiovasc Surg
47. Matata BM, Sosnowski AW, Galinanes M. Off-pump bypass graft operation significantly reduces oxidative stress and inflammation. Ann Thorac Surg
48. Motallebzadeh R, Kanagasabay R, Bland M, et al. S100 protein and its relation to cerebral microemboli in on-pump and off-pump coronary artery bypass surgery. Eur J Cardiothorac Surg
49. Muneretto C, Bisleri G, Negri A, et al. Off-pump coronary artery bypass surgery technique for total arterial myocardial revascularization: A prospective randomized study. Ann Thorac Surg
50. Nathoe HM, van Dijk D, Jansen EWL, et al. A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med
51. Penttila HJ, Lepojärvi MVK, Kiviluoma KT, et al. Myocardial preservation during coronary surgery with and without cardiopulmonary bypass. Ann Thorac Surg
52. Puskas JD, Williams WH, Duke PG, Staples JR, et al. Off-pump coronary artery bypass grafting provides complete revascularization with reduced myocardial injury, complete revascularization with reduced myocardial injury, transfusion requirements, and length of stay: A prospective randomized comparison of two hundred unselected patients undergoing off-pump versus conventional coronary artery bypass grafting. J Thorac Cardiovasc Surg
53. Puskas JD, Williams WH, Mahoney EM, et al. Off-pump vs conventional coronary artery bypass grafting: Early and 1-year graft patency, cost, and quality-of-life outcomes: a randomized trial. JAMA
54. Sahlman A, Ahonen J, Nemlander A, et al. Myocardial metabolism on off-pump surgery; a randomized study of 50 cases. Scand Cardiovasc J
55. Schulze C, Conrad N, Schutz A, et al. Reduced expression of systemic proinflammatory cytokines after off-pump versus conventional coronary artery bypass grafting. Thorac Cardiovasc Surg
56. Straka Z, Widimisky P, Jirasek K, et al. Off-pump versus on-pump coronary surgery: Final results from a prospective randomized study PRAGUE-4. Ann Thorac Surg
57. Selvanayagam JB, Petersen SE, Francis JM, et al. Effects of off-pump versus on-pump coronary surgery on reversible and irreversible myocardial injury. A randomized trial using cardiovascular magnetic resonance imaging and biochemical markers. Circulation
58. Tang ATM, Knott J, Nanson J, et al. A prospective randomized study to evaluate the renoprotective action of beating heart coronary surgery in low risk patients. Eur J Cardiothorac Surg
59. van Dijk D, Nierich AP, Jansen EWL, et al. for the Octopus Study Group. Early outcomes after off-pump versus on-pump coronary bypass surgery. Results from a randomized study. Circulation
60. van Dijk D, Jansen EWL, Hijman R, et al. for the Octopus Study Group. Cognitive outcome after off-pump and on-pump coronary artery bypass graft surgery. A randomized trial. JAMA
61. van Dijk D, Moons KGM, Keizer AMA, et al. for the Octopus Study Group. Association between early and three month cognitive outcome after off-pump and on-pump coronary bypass surgery. Heart
62. Vural KM, Tasdemir O, Karagoz H, et al. Comparison of the early results of coronary artery bypass grafting with and without extracorporeal circulation. Thorac Cardiovasc Surg
63. Wandschneider W, Thalmann M, Trampitsch E, et al. Off-pump coronary bypass operations significantly reduce S100 release: An indicator for less cerebral damage? Ann Thorac Surg
64. Wehlin L, Vedin J, Vaage J, Lundahl J. Activation of complement and leukocyte receptors during on- and off pump coronary artery bypass surgery. Eur J Cardiothorac Surg
65. Wildhirt SM, Schulz C, Conrad N, et al. Expressionvon TNF-a und loslichen Adhasionsmolekulen nach koronarchirurgischen Eingriffen mit und onhe extgrakorporaler Zikulation. Zeitschrift fur Herz-, Throax- und GefaBchirungle
66. Wildhirt SM, Schulze C, Conrad N, et al. Reduced myocardial cellular damage and lipid peroxidation in off-pump versus conventional coronary artery bypass grafting. Eur J Med Res
67. Wildhirt SM, Schulze C, Egi K, et al. Reduction of systemic and cardiac adhesion molecule expression after off-pump versus conventional coronary artery bypass grafting. Shock
68. Zamvar V, Williams D, Hall J, et al. Assessment of neurocognitive impairment after off-pump and on-pump techniques for coronary artery bypass graft surgery: prospective randomized controlled trial. BMJ
69. Lund C, Hol PK, Lundbland R, et al. Comparison of cerebral embolization during off-pump and on-pump coronary artery bypass surgery. Ann Thorac Surg
70. Meharwal ZS, Trehan N. Off-pump coronary artery bypass grafting in patients with left ventricular dysfunction. Heart Surg Forum
71. Chamberlain MH, Ascione R, Reeves BC, et al. Evaluation of the effectiveness of off-pump coronary artery bypass grafting in high-risk patients: An observational study. Ann Thorac Surg
72. Ascione R, Nason G, Al-Ruzzeh S, et al. Coronary revascularization with or without cardiopulmonary bypass in patients with preoperative nondialysis-dependent renal insufficiency. Ann Thorac Surg
73. Deuse T, Detter C, Samuel V, et al. Early and midterm results after coronary artery bypass grafting with and without cardiopulmonary bypass: Which patient population benefits the most? Heart Surg Forum
74. Dewey TM, Magee MJ, Edgerton JR, et al. Off-pump bypass grafting is safe in patients with left main coronary disease. Ann Thorac Surg
75. Yokoyama T, Baumgartner FJ, Ghiessari A, et al. Off-pump versus on-pump coronary bypass in high-risk subgroups. Ann Thorac Surg
76. Ascione R, Narayan P, Rogers CA, et al. Early and midterm clinical outcome in patients with severe left ventricular dysfunction undergoing coronary artery surgery. Ann Thorac Surg
77. Al-Ruzzeh S, George S, Yacoub M, Amrani M. The clinical outcome of off-pump coronary artery bypass surgery in the elderly patients. Eur J Cardiothorac Surg
78. Dewey TM, Herbert MA, Prince SL, et al. Avoidance of cardiopulmonary bypass improves early survival in multivessel coronary artery bypass patients with poor ventricular function. Heart Surg Forum
79. Meharwal ZS, Trehan N. Is off-pump coronary artery bypass surgery safe for left main coronary artery stenosis? Indian Heart J
80. Ricci M, Karamanoukian HL, Abraham R, et al. Stroke in octogenarians undergoing coronary artery surgery with and without cardiopulmonary bypass. Ann Thorac Surg
81. Sharony R, Bizekis CS, Kanchuger M, et al. Off-pump coronary artery bypass grafting reduces mortality and stroke in patients with atheromatous aortas: A case control study. Circulation
82. Shennib H, Endo M, Benhamed O, Morin JF. Surgical revascularization in patients with poor left ventricular function: On- or off-pump? Ann Thorac Surg
83. Tashiro T, Nakamura K, Morishige N, et al. Off-pump coronary artery bypass grafting in patients with end-stage renal disease on hemodialysis. J Card Surg
84. Petro KR, Dullum MKC, Garcia JM, et al. Minimally invasive coronary revascularization in women: A safe approach for a high-risk group. Heart Surg Forum
85. Pompilio G, Antona C, Cannata A, et al. Coronary surgery without extracorporeal circulation: the short term results in high-risk patients. G Ital Cardiol
86. Meharwal ZS, Mishra YK, Kohkli V, et al. Off-pump multivessel coronary artery surgery in high-risk patients. Ann Thorac Surg
87. Ochi M, Hatori N, Saji Y, et al. Application of off-pump coronary artery bypass grafting for patient with acute coronary syndrome requiring emergency surgery. Ann Thorac Cardiovasc Surg
88. Magee MJ, Dewey TM, Acuff T, et al. Influence of diabetes on mortality and morbidity: Off-pump coronary artery bypass grafting versus coronary artery bypass grafting with cardiopulmonary bypass. Ann Thorac Surg
89. Locker C, Shapira I, Paz Y, et al. Emergency myocardial revascularization for acute myocardial infarction: survival benefits of avoiding cardiopulmonary bypass. Eur J Cardiothorac Surg
90. Hoff SJ, Ball SK, Coltharp WH, et al. Coronary artery bypass in patients 80 years and over: Is off-pump the operation of choice? Ann Thorac Surg
91. Kilo J, Baumer H, Czerny M, et al. Target vessel revascularization without cardiopulmonary bypass in elderly high-risk patients. Ann Thorac Surg
92. Kirali K, Rabus MB, Yakut N, et al. Early- and long-term comparison of the on- and off-pump bypass surgery in patients with left ventricular disease. Heart Surg Forum
93. Goldstein DJ, Beauford RB, Luk B, et al. Multivessel off-pump revascularization in patients with severe left ventricular dysfunction. Eur J Cardiothorac Surg
94. Al-Ruzzeh S, Athanasiou T, George S, et al. Is the use of cardiopulmonary bypass for multivessel coronary artery bypass surgery an independent predictor of operative mortality in patients with ischemic left ventricular dysfunction? Ann Thorac Surg
95. Abraham R, Karamanoukian HL, Jajkowski MR, et al. Does avoidance of cardiopulmonary bypass decrease the incidence of stroke in diabetics undergoing coronary surgery? Heart Surg Forum
96. Demers P, Cartier R. Multivessel off-pump coronary artery bypass surgery in the elderly. Eur J Cardiothorac Surg
97. Arom KV, Flavin TF, Emery RW, et al. Safety and efficacy of off-pump coronary artery bypass grafting. Ann Thorac Surg
98. Bellegham YV, Caes F, Maene L, et al. Off-pump coronary surgery: surgical strategy for the high-risk patient. Cardiovasc Surg
99. Gaudino M, Glieca F, Alessandrini F, et al. High risk coronary artery bypass patient: Incidence, surgical strategies, and results. Ann Thorac Surg
100. Martinovic I, Farah I, Mair R, et al. Reduced mortality and cerebrovascular morbidity with off-pump coronary artery bypass grafting surgery in octogenarians. Heart Surg Forum
101. Boyd WD, Desai ND, Del Rizzo DF, et al. Off-pump surgery decreases postoperative complications and resource utilization in the elderly. Ann Thorac Surg
102. Boyd WD, Desai ND, Novick RJ, et al. Use of cardiopulmonary bypass in high-risk patients is a predictor of adverse outcome. Semin Cardiothorac Vasc Anesth
103. Zapolanski A, Mengarelli L, Pliam MB, Shaw RE. Diabetics undergoing beating heart surgery have better outcomes compared with conventional coronary artery bypass surgery. Heart Surg Forum
104. Farmas AI, Pacholewicz JK, Kaperczak J, et al. Results of myocardial revascularization in patients with left main stenosis (LM) with and without cardiopulmonary bypass. Heart Surg Forum
105. Ascione R, Reeves BC, Rees K, Angelini GD. Effectiveness of coronary artery bypass grafting with or without cardiopulmonary bypass in overweight patients. Circulation
106. Karthik S, Musleh G, Grayson AD, et al. Effect of avoiding cardiopulmonary bypass in non-elective coronary artery bypass surgery: a propensity score analysis. Eur J Cardiothorac Surg
107. Balkhy HH, Quinn CC, Lois KH, Munsch CM. Routine multivessel off pump coronary bypass beneficial in women? In hospital outcomes in 131 consecutive female patients. Heart Surg Forum
108. Beauford RB, Saunders CR, Niemeier LA, et al. Is off-pump revascularization better for patients with non-dialysis-dependent renal insufficiency? Heart Surg Forum
109. McKay RG, Mennett RA, Gallagher RC, et al. A comparison of on-pump vs off-pump coronary artery bypass surgery among low, intermediate, and high-risk patients: The Hartford Hospital experience. Connecticut Medicine
110. Magovern JA, Benckart DH, Landreneau RJ, et al. Morbidity, cost, and six-month outcome of minimally invasive direct coronary artery bypass grafting. Ann Thorac Surg
111. Racz MJ, Hannan EL, Isom OW, et al. A comparison of short- and long-term outcomes after off-pump and on-pump coronary artery bypass graft surgery with steronotomy. J Am Coll Cardiol
112. Edgerton JR, Dewey TM, Magee MJ, et al. Conversion in off-pump coronary artery bypass grafting: An analysis of predictors and outcomes. Ann Thorac Surg
113. Mathur AN, Pather R, Widjanarko J, et al. Off-pump coronary artery bypass: the Sudbury experience. Can J Cardiol
114. Soltoski P, Salerno T, Levinsky L, et al. Conversion to cardiopulmonary bypass in off-pump coronary artery bypass grafting: its effect on outcome. J Card Surg
115. Iacò AL, Contini M, Teodori G, et al. Off or on bypass: What is the safety threshold? Ann Thorac Surg
116. Mujanovic E, Kabil E, Hadziselimovic M, et al. Conversions in off-pump coronary surgery. Heart Surg Forum
117. Jones EL, Weintraub WS. Surgery for acquired heart disease. The importance of completeness of revascularization during long-term follow-up after coronary artery operations. J Thorac Cardiovasc Surg
118. Buda AJ, Macdonald IL, Anderson MJ, et al. Long-term results following coronary bypass operation. Importance of preoperative actors and complete revascularization. J Thorac Cardiovasc Surg
119. Bell MR, Gersh BJ, Schaff HV, et al. Effect of completeness of revascularization on long-term outcome of patients with three-vessel disease undergoing coronary artery bypass surgery. A report of the Coronary Artery Surgery Study (CASS) Registry. Circulation
120. Gundry SR, Romano MA, Shattuck OH, et al. Seven-year follow-up of coronary artery bypasses performed with and without cardiopulmonary bypass. J Thorac Cardiovasc Surg
121. Cleveland JC Jr., Shroyer, ALW, Chen AY, et al. Off-pump coronary artery bypass grafting decreases risk-adjusted mortality and morbidity. Ann Thorac Surg
122. Plomondon ME, Cleveland JC Jr, Ludwig ST, et al. Off-pump coronary artery bypass is associated with improved risk-adjusted outcomes. Ann Thorac Surg
123. Jansen EW, Borst C, Lahpor JR, et al. Coronary artery bypass grafting without cardiopulmonary bypass using the octopus method: results in the first one hundred patients. J Thorac Cardiovasc Surg
124. Hart JC, Spooner TH, Pym J, et al. A review of 1,582 consecutive Octopus off-pump coronary bypass patients. Ann Thorac Surg
125. Boening A, Freidrich C, Hedderich J, et al. Early and medium-term results after on-pump and off-pump coronary artery surgery: A propensity score analysis. Ann Thorac Surg
126. Mehran R, Subramanian V, Mack M, et al. Angiographic patency of LIMA-LAD anastomosis after MIDCAB compared to conventional CABG: Results from the POEM Trial. J Am Coll Cardiol
127. Lund O, Christensen J, Holme S, et al. On-pump versus off-pump coronary artery bypass: independent risk factors and off-pump graft patency. Eur J Cardiothorac Surg
128. Kim K-B, Lim C, Lee C, et al. Off-pump coronary artery bypass may decrease the patency of saphenous vein grafts. Ann Thorac Surg
129. Semrad M, Bodlak P, Stritesky M, et al. Off-pump coronary artery bypass grafting. The 1st Medical Faculty of Charles University study. Sb Lek
130. Matsuura K, Kobayashi J, Tagusari O, et al. Rationale for off-pump coronary revascularization to small branches - Angiographic study of 1,283 anastomoses in 408 patients. Ann Thorac Surg
131. Puskas JD, Thourani VH, Marshall JJ, et al. Clinical outcomes, angiographic patency, and resource utilization in 200 consecutive off-pump coronary bypass patients. Ann Thorac Surg
132. Omeroglu SN, Kirali K, Guler M, et al. Midterm angiographic assessment of coronary artery bypass grafting without cardiopulmonary bypass. Ann Thorac Surg
133. Murkin JM. Neurological outcomes after OPCAB: How much better is it? Heart Surg Forum
134. van Dijk D, Keizer AM, Diephuis JC, et al. Neurocognitive dysfunction after coronary artery bypass surgery: a systematic review. J Thorac Cardiovasc Surg
135. Anderson RE, Li T-Q, Hindmarsh T, et al. Increased extracellular brain water after coronary artery bypass grafting is avoided by off-pump surgery. J Cardiothor Vasc Anesth
136. Bowles BJ, Lee JD, Dang CR, et al. Coronary artery bypass performed without the use of cardiopulmonary bypass is associated with reduced cerebral microemboli and improved clinical results. Chest
137. Bhasker Rao B, Van Himbergen D, Edmunds LH Jr, et al. Evidence for improved cerebral function after minimally invasive bypass surgery. J Card Surg
138. Immer FF, Berdat PA, Immer-Bansi AS, et al. Benefit to quality of life after off-pump versus on-pump coronary bypass surgery. Ann Thorac Surg
139. Al-Ruzzeh S, Nakamura K, Athanasiou T, et al. Does off-pump coronary artery bypass (OPCAB) surgery improve the outcome in high-risk patients?: a comparative study of 1398 high-risk patients. Eur J Cardiothorac Surg
140. Gaudino M, Glieca F, Alessandrini F, et al. The unclampable ascending aorta in coronary artery bypass patients: A surgical challenge of increasing frequency. Circulation
141. Sharony R, Grossi EA, Saunders PC, et al. Propensity case-matched analysis of off-pump coronary artery bypass grafting in patients with atheromatous aortic disease. J Thorac Cardiovasc Surg
142. Czerny M, Zimpfer D, Kilo J, et al. Redo coronary artery bypass grafting with and without cardiopulmonary bypass in the elderly. Heart Surg Forum
143. Kurlansky PA. Is there a hypercoagulable state after off-pump coronary artery bypass surgery? What do we know and what can we do? J Thorac Cardiovasc Surg
© 2005 Lippincott Williams & Wilkins, Inc.